Simon Michel, CEO of Ypsomed and member of Switzerland’s National Council, shares his journey in the medtech industry. He discusses the evolution of Ypsomed from its roots in insulin delivery to broader chronic care solutions. The conversation dives into the challenges of balancing R&D in Switzerland with manufacturing abroad, the strategy behind going public, and the necessity for political involvement to support entrepreneurs. Michel also reflects on maintaining Swiss values while pursuing global expansion.